We must shift the pattern of signifiers, learn to decode antizionist maneuvers, and develop the tools to block them in real ...

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...